Search

Your search keyword '"Pellaton, Céline' showing total 4 results
Start Over Author "Pellaton, Céline Publisher nature publishing group
4 results on '"Pellaton, Céline'

1. Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study

Author

Raineri, Alessia; https://orcid.org/0009-0007-7128-9656, Radtke, Thomas; https://orcid.org/0000-0002-1723-1070, Rueegg, Sonja, Haile, Sarah R; https://orcid.org/0000-0002-4704-6570, Menges, Dominik; https://orcid.org/0000-0001-5970-1846, Ballouz, Tala; https://orcid.org/0000-0003-2334-8600, Ulyte, Agne; https://orcid.org/0000-0001-7419-9778, Fehr, Jan; https://orcid.org/0000-0003-1113-9895, Cornejo, Daniel L, Pantaleo, Giuseppe; https://orcid.org/0000-0003-3651-2721, Pellaton, Céline; https://orcid.org/0000-0003-2090-9572, Fenwick, Craig; https://orcid.org/0000-0002-9435-0110, Puhan, Milo A; https://orcid.org/0000-0003-4721-1879, Kriemler, Susi; https://orcid.org/0000-0002-3384-7940, Raineri, Alessia; https://orcid.org/0009-0007-7128-9656, Radtke, Thomas; https://orcid.org/0000-0002-1723-1070, Rueegg, Sonja, Haile, Sarah R; https://orcid.org/0000-0002-4704-6570, Menges, Dominik; https://orcid.org/0000-0001-5970-1846, Ballouz, Tala; https://orcid.org/0000-0003-2334-8600, Ulyte, Agne; https://orcid.org/0000-0001-7419-9778, Fehr, Jan; https://orcid.org/0000-0003-1113-9895, Cornejo, Daniel L, Pantaleo, Giuseppe; https://orcid.org/0000-0003-3651-2721, Pellaton, Céline; https://orcid.org/0000-0003-2090-9572, Fenwick, Craig; https://orcid.org/0000-0002-9435-0110, Puhan, Milo A; https://orcid.org/0000-0003-4721-1879, and Kriemler, Susi; https://orcid.org/0000-0002-3384-7940

Abstract

Understanding the development of humoral immune responses of children and adolescents to SARS-CoV-2 is essential for designing effective public health measures. Here we examine the changes of humoral immune response in school-aged children and adolescents during the COVID-19 pandemic (June 2020 to July 2022), with a specific interest in the Omicron variant (beginning of 2022). In our study “Ciao Corona”, we assess in each of the five testing rounds between 1874 and 2500 children and adolescents from 55 schools in the canton of Zurich with a particular focus on a longitudinal cohort (n=751). By July 2022, 96.9% (95% credible interval 95.3–98.1%) of children and adolescents have SARS-CoV-2 anti-spike IgG (S-IgG) antibodies. Those with hybrid immunity or vaccination have higher S-IgG titres and stronger neutralising responses against Wildtype, Delta and Omicron BA.1 variants compared to those infected but unvaccinated. S-IgG persist over 18 months in 93% of children and adolescents. During the study period one adolescent was hospitalised for less than 24 hours possibly related to an acute SARS-CoV-2 infection. These findings show that the Omicron wave and the rollout of vaccines boosted S-IgG titres and neutralising capacity. Trial registration number: NCT04448717. https://clinicaltrials.gov/ct2/show/NCT04448717.

Published
2023

2. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort

Author

Menges, Dominik; https://orcid.org/0000-0001-5970-1846, Zens, Kyra D; https://orcid.org/0000-0001-7979-076X, Ballouz, Tala; https://orcid.org/0000-0003-2334-8600, Caduff, Nicole; https://orcid.org/0000-0002-7479-5446, Llanas-Cornejo, Daniel, Aschmann, Hélène E; https://orcid.org/0000-0003-1234-4321, Domenghino, Anja; https://orcid.org/0000-0002-8617-409X, Pellaton, Céline; https://orcid.org/0000-0003-2090-9572, Perreau, Matthieu, Fenwick, Craig; https://orcid.org/0000-0002-9435-0110, Pantaleo, Giuseppe; https://orcid.org/0000-0003-3651-2721, Kahlert, Christian R; https://orcid.org/0000-0002-0784-3276, Münz, Christian; https://orcid.org/0000-0001-6419-1940, Puhan, Milo A; https://orcid.org/0000-0003-4721-1879, Fehr, Jan S; https://orcid.org/0000-0003-1113-9895, Menges, Dominik; https://orcid.org/0000-0001-5970-1846, Zens, Kyra D; https://orcid.org/0000-0001-7979-076X, Ballouz, Tala; https://orcid.org/0000-0003-2334-8600, Caduff, Nicole; https://orcid.org/0000-0002-7479-5446, Llanas-Cornejo, Daniel, Aschmann, Hélène E; https://orcid.org/0000-0003-1234-4321, Domenghino, Anja; https://orcid.org/0000-0002-8617-409X, Pellaton, Céline; https://orcid.org/0000-0003-2090-9572, Perreau, Matthieu, Fenwick, Craig; https://orcid.org/0000-0002-9435-0110, Pantaleo, Giuseppe; https://orcid.org/0000-0003-3651-2721, Kahlert, Christian R; https://orcid.org/0000-0002-0784-3276, Münz, Christian; https://orcid.org/0000-0001-6419-1940, Puhan, Milo A; https://orcid.org/0000-0003-4721-1879, and Fehr, Jan S; https://orcid.org/0000-0003-1113-9895

Abstract

To better understand the development of SARS-CoV-2-specific immunity over time, a detailed evaluation of humoral and cellular responses is required. Here, we characterize anti-Spike (S) IgA and IgG in a representative population-based cohort of 431 SARS-CoV-2-infected individuals up to 217 days after diagnosis, demonstrating that 85% develop and maintain anti-S responses. In a subsample of 64 participants, we further assess anti-Nucleocapsid (N) IgG, neutralizing antibody activity, and T cell responses to Membrane (M), N, and S proteins. In contrast to S-specific antibody responses, anti-N IgG levels decline substantially over time and neutralizing activity toward Delta and Omicron variants is low to non-existent within just weeks of Wildtype SARS-CoV-2 infection. Virus-specific T cells are detectable in most participants, albeit more variable than antibody responses. Cluster analyses of the co-evolution of antibody and T cell responses within individuals identify five distinct trajectories characterized by specific immune patterns and clinical factors. These findings demonstrate the relevant heterogeneity in humoral and cellular immunity to SARS-CoV-2 while also identifying consistent patterns where antibody and T cell responses may work in a compensatory manner to provide protection.

Published
2022

3. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort

Author

Menges, Dominik, Zens, Kyra D, Ballouz, Tala, Caduff, Nicole, Llanas-Cornejo, Daniel, Aschmann, Hélène E, Domenghino, Anja, Pellaton, Céline, Perreau, Matthieu, Fenwick, Craig, Pantaleo, Giuseppe, Kahlert, Christian R, Münz, Christian, Puhan, Milo A, Fehr, Jan S, University of Zurich, and Puhan, Milo A

Subjects
Immunity, Cellular, 1000 Multidisciplinary, Multidisciplinary, SARS-CoV-2, COVID-19, General Physics and Astronomy, 610 Medicine & health, 1600 General Chemistry, General Chemistry, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), Antibodies, Viral, 10263 Institute of Experimental Immunology, Antibodies, Neutralizing, General Biochemistry, Genetics and Molecular Biology, 3100 General Physics and Astronomy, Immunity, Humoral, 1300 General Biochemistry, Genetics and Molecular Biology, Immunoglobulin G, Spike Glycoprotein, Coronavirus, Humans
Abstract

To better understand the development of SARS-CoV-2-specific immunity over time, a detailed evaluation of humoral and cellular responses is required. Here, we characterize anti-Spike (S) IgA and IgG in a representative population-based cohort of 431 SARS-CoV-2-infected individuals up to 217 days after diagnosis, demonstrating that 85% develop and maintain anti-S responses. In a subsample of 64 participants, we further assess anti-Nucleocapsid (N) IgG, neutralizing antibody activity, and T cell responses to Membrane (M), N, and S proteins. In contrast to S-specific antibody responses, anti-N IgG levels decline substantially over time and neutralizing activity toward Delta and Omicron variants is low to non-existent within just weeks of Wildtype SARS-CoV-2 infection. Virus-specific T cells are detectable in most participants, albeit more variable than antibody responses. Cluster analyses of the co-evolution of antibody and T cell responses within individuals identify five distinct trajectories characterized by specific immune patterns and clinical factors. These findings demonstrate the relevant heterogeneity in humoral and cellular immunity to SARS-CoV-2 while also identifying consistent patterns where antibody and T cell responses may work in a compensatory manner to provide protection.

Published
2022
Full Text
View/download PDF

4. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.

Author

Fenwick C, Turelli P, Ni D, Perez L, Lau K, Herate C, Marlin R, Lana E, Pellaton C, Raclot C, Esteves-Leuenberger L, Campos J, Farina A, Fiscalini F, Dereuddre-Bosquet N, Relouzat F, Abdelnabi R, Foo CS, Neyts J, Leyssen P, Lévy Y, Pojer F, Stahlberg H, LeGrand R, Trono D, and Pantaleo G

Subjects
Animals, Antibodies, Monoclonal, Antibodies, Viral, Cryoelectron Microscopy, Epitopes, Haplorhini, Humans, Membrane Glycoproteins, Neutralization Tests, Spike Glycoprotein, Coronavirus, Viral Envelope Proteins, COVID-19, SARS-CoV-2
Abstract

The SARS-CoV-2 Omicron variant has very high levels of transmission, is resistant to neutralization by authorized therapeutic human monoclonal antibodies (mAb) and is less sensitive to vaccine-mediated immunity. To provide additional therapies against Omicron, we isolated a mAb named P2G3 from a previously infected vaccinated donor and showed that it has picomolar-range neutralizing activity against Omicron BA.1, BA.1.1, BA.2 and all other variants tested. We solved the structure of P2G3 Fab in complex with the Omicron spike using cryo-electron microscopy at 3.04 Å resolution to identify the P2G3 epitope as a Class 3 mAb that is different from mAb-binding spike epitopes reported previously. Using a SARS-CoV-2 Omicron monkey challenge model, we show that P2G3 alone, or in combination with P5C3 (a broadly active Class 1 mAb previously identified), confers complete prophylactic or therapeutic protection. Although we could select for SARS-CoV-2 mutants escaping neutralization by P2G3 or by P5C3 in vitro, they had low infectivity and 'escape' mutations are extremely rare in public sequence databases. We conclude that this combination of mAbs has potential as an anti-Omicron drug., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results